ATE442387T1 - Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung - Google Patents

Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung

Info

Publication number
ATE442387T1
ATE442387T1 AT02730429T AT02730429T ATE442387T1 AT E442387 T1 ATE442387 T1 AT E442387T1 AT 02730429 T AT02730429 T AT 02730429T AT 02730429 T AT02730429 T AT 02730429T AT E442387 T1 ATE442387 T1 AT E442387T1
Authority
AT
Austria
Prior art keywords
interleukin
cell receptor
following infection
progression
aids
Prior art date
Application number
AT02730429T
Other languages
English (en)
Inventor
John Marchalonis
Ronald Watson
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Application granted granted Critical
Publication of ATE442387T1 publication Critical patent/ATE442387T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Confectionery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02730429T 2001-05-18 2002-05-17 Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung ATE442387T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0112126.8A GB0112126D0 (en) 2001-05-18 2001-05-18 Composition
PCT/GB2002/002323 WO2002094860A2 (en) 2001-05-18 2002-05-17 Dimerized t-cell receptor fragment, its compositions and use

Publications (1)

Publication Number Publication Date
ATE442387T1 true ATE442387T1 (de) 2009-09-15

Family

ID=9914850

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02730429T ATE442387T1 (de) 2001-05-18 2002-05-17 Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung

Country Status (7)

Country Link
US (1) US7998926B2 (de)
EP (1) EP1389219B1 (de)
AT (1) ATE442387T1 (de)
AU (1) AU2002302751A1 (de)
DE (1) DE60233654D1 (de)
GB (1) GB0112126D0 (de)
WO (1) WO2002094860A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323174B1 (en) * 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
US8034773B2 (en) * 2004-02-05 2011-10-11 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
ZA200608178B (en) 2004-03-30 2008-10-29 Roussy Inst Gustave Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
AU2005247049A1 (en) * 2004-05-27 2005-12-08 Novozymes Biopharma Au Limited Treatment of inflammatory airway disease
WO2006063028A2 (en) * 2004-12-07 2006-06-15 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
US7811995B2 (en) * 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
US8496942B2 (en) * 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
EP3288576A4 (de) 2015-04-27 2019-01-16 Susavion Biosciences, Inc. Zusammensetzungen und verfahren zur behandlung von krebs und persistenten virusinfektionen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
WO1991010736A2 (en) * 1990-01-19 1991-07-25 Dana Farber Cancer Institute CLONING AND CHARACTERIZATION OF THE CD3θ SUBUNIT
WO1992001715A1 (en) * 1990-07-19 1992-02-06 The Board Of Trustees Of The Leland Stanford Junior University Soluble cell-surface dimeric proteins
EP1978095A1 (de) * 1993-02-12 2008-10-08 The Board Of Trustees Of The Leland Stanford Junior University Regulierte Transkription gezielter Gene und anderer biologischer Ereignisse
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
WO1996021028A2 (en) * 1995-01-03 1996-07-11 Procept, Inc. Soluble heterodimeric t cell receptors and their antibodies
US6150337A (en) 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US5714577A (en) * 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US5962319A (en) 1997-05-19 1999-10-05 Bml, Inc. Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
US5911990A (en) * 1996-08-13 1999-06-15 Arizona Board Of Regents On Behalf Of The University Of Arizona T-cell receptor peptides and methods for preventing the progression to AIDS in an animal model
IL119938A (en) * 1996-12-30 2005-08-31 Yissum Res Dev Co Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells
US7323174B1 (en) * 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon

Also Published As

Publication number Publication date
EP1389219A2 (de) 2004-02-18
GB0112126D0 (en) 2001-07-11
US20040248192A1 (en) 2004-12-09
EP1389219B1 (de) 2009-09-09
AU2002302751A1 (en) 2002-12-03
DE60233654D1 (de) 2009-10-22
US7998926B2 (en) 2011-08-16
WO2002094860A2 (en) 2002-11-28
WO2002094860A3 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
WO2006034334A3 (en) Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
RS20130234A1 (en) Therapeutic human anti-il-1r1 monoclonal antibody
WO2006023665A3 (en) Il-1 antagonist formulations
IL141021A (en) Use of copolymer-like polypeptide-1 to prepare a drug to treat autoimmune diseases
HK1088840A1 (en) Stable analogs of glp-1 glp-1
MX9801732A (es) Anticuerpos anti-cd4 recombinantes para la terapia a humanos.
NL300013I1 (nl) Nieuwe protein met TNF-remmende werking en hun ber
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
JP2004518624A5 (de)
ES2187520T3 (es) Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina.
CA2106762A1 (en) Bradykinin Antagonist Peptides
ATE442387T1 (de) Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung
YU394A (sh) Novi peptidi koji deluju kao antagonisti opijatskih receptora i postupci za njihovu izradu
DK1447414T3 (da) Antagonistpeptider af carcinoembronisk antigen (CEA)
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
PT996726E (pt) Proteina de membrana de celulas t (tirc7) peptidos e anticorpos dela derivados e suas utilizacoes
ES2123556T3 (es) Peptidos de tipo bradiquinina.
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
EP1250358B1 (de) Therapeutische peptide
NO975565L (no) Benstimulerende faktor
TR200003498T2 (tr) Amino asit sekansından oluşan bir polipetit, bunun aşıları ve kullanımları
HK1092162A1 (en) Biologically active peptides comprising isoleucyl-valyl-threonyl- asparaginyl-threonyl-threonine (ivtntt)
WO2001051512A3 (en) Human and parasite orphan receptor proteins
IL154777A0 (en) Il-6 receptor/il-6 chimera in huntington's disease
DE60223232D1 (de) Mucinpeptid mit immunstärkenden eigenschaften

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties